Amicus Therapeutics Inc [NASDAQ: FOLD] price surged by 1.93 percent to reach at $0.24. The company report on February 1, 2024 at 7:00 AM that Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024.
The one-year FOLD stock forecast points to a potential upside of 35.22. The average equity rating for FOLD stock is currently 1.55, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Amicus Therapeutics Inc [FOLD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FOLD shares is $19.56 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FOLD stock is a recommendation set at 1.55. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Amicus Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on December 19, 2023.
The Average True Range (ATR) for Amicus Therapeutics Inc is set at 0.49, with the Price to Sales ratio for FOLD stock in the period of the last 12 months amounting to 9.98. The Price to Book ratio for the last quarter was 27.64, with the Price to Cash per share for the same quarter was set at 0.96.
FOLD Stock Performance Analysis:
Amicus Therapeutics Inc [FOLD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.24. With this latest performance, FOLD shares dropped by -11.03% in over the last four-week period, additionally sinking by -6.56% over the last 6 months – not to mention a drop of -2.84% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 49.00, with the RSI for the last a single of trading hit 48.37, and the three-weeks RSI is set at 50.32 for Amicus Therapeutics Inc [FOLD]. The present Moving Average for the last 50 days of trading for this stock 12.44, while it was recorded at 12.61 for the last single week of trading, and 12.18 for the last 200 days.
Insight into Amicus Therapeutics Inc Fundamentals:
Amicus Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.40 and a Current Ratio set at 2.73.
FOLD Stock EPS
With the latest financial reports released by the company, Amicus Therapeutics Inc posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -46.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FOLD.
Amicus Therapeutics Inc [FOLD] Institutonal Ownership Details
The top three institutional holders of FOLD stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in FOLD stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in FOLD stock with ownership which is approximately 5.8325%.
